Title of study
Case-Control Study on Parkinson's Disease Among Mutualité Sociale Agricole Affliates in Five Départements
Name of Principal Investigator - Title
Name of Principal Investigator - First name
Name of Principal Investigator - Last name
Address of institution -Institution
Address of institution - Street address
16 Avenue Paul Vaillant Couturier
Address of institution - City
Address of institution - Postcode
ANR - ANSES - France Parkinson
Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?
Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)
To study the association of professional exposure to pesticides with Parkinson's disease and the role of gene-environment interactions
Q2b. What distinguishes this case-control study from other studies?
Detailed individual data on professional exposure to pesticides in farmers. Population-based study.
Q3a. i) Number of publications that involve use of your cohort to date
Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available
1. Chapuis, J., F. Moisan, G. Mellick, A. Elbaz, P. Silburn, F. Pasquier, D. Hannequin, C. Lendon, D. Campion, P. Amouyel and J. C. Lambert (2008). "Association study of the NEDD9 gene with the risk of developing Alzheimer's and Parkinson's disease." Hum Mol. Genet 17(18): 2863-2867.
2. Dutheil, F., P. Beaune, C. Tzourio, M.-A. Loriot and A. Elbaz (2010). "Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson's disease." Arch. Neurol 67(6): 739-745.
3. Elbaz, A., J. Clavel, P. J. Rathouz, F. Moisan, J. P. Galanaud, B. Delemotte, A. Alpérovitch and C. Tzourio (2009). "Professional exposure to pesticides and Parkinson's disease." Ann Neurol 66: 494-504.
Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study
Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:
Q4a. Study criteria: what is the age range of participants at recruitment? To:
Q4b. Study criteria: what are the inclusion criteria?
Case subjects: first LDD requests for Parkinson's disease (18-75 years old). Controls: treatment guarantee requests (random); matched to cases according to age, gender, and département of residence.
Q4c. Study criteria: what are the exclusion criteria?
Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?
Q5b. What is the expected number of control participants?
Q6a. Please describe what measures are used to characterise participants
Q6b. Are there additional measures for participants with the clinical disorder?
Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?
Q7. What is the study design?
Q8. Are your cases matched by
Q9a. Does your study includes a specialised subset of control participants?
Q9b. If your study includes a specialised subset of control participants please describe
Q10a. Is data collection for this study
Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?
Q12. Is there a system in place to enable re-contact with patients for future studies?
Q13a. Please give information on data stored in a database (1)
Data summarised in database
Q13a. Please give information on data stored in a database (2)
Q13a. Please give information on data stored in a database (3)
Q13a. Please give information on data stored in a database (4)
Q13a. Please give information on data stored in a database (5)
Please specify language used
Q13b. Please give information on how data is held as individual records
Q14a. Are data available to other groups?
Q14b. If data is available to other groups what is the access policy/mechanisms for access?
Access through collaboration with PI only
Q15. What data sharing policy is specified as a condition of use?
Q16a. Are tissues/samples/DNA available to other groups?
Q16b i) If yes, please describe below
Q16b. ii) In what form are tissues/samples/DNA supplied?
Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?
Q17. Is information on biological characteristics available to other groups?
Types: Case Control Studies
Member States: France
Diseases: Parkinson's disease & PD-related disorders
Database Categories: N/A
Database Tags: N/A
Export as PDF